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cardia (CPVT) is an inheritable cardiac disease predisposing to
malignant ventricular arrhythmias.
OBJECTIVE We aimed to explore the incidence and severity of
ventricular arrhythmias in patients with CPVT before the initiation
of β-blocker treatment, when treated with β1-selective β-blockers,
and when treated with nadolol.
METHODS In this study, 34 patients with CPVT were included (mean
age 34 19 years; 15 (44%) women; 30 (88%) ryanodine receptor 2
variant positive). We performed 3 bicycle exercise stress tests in each
patient: (1) before the initiation of β-blocker treatment, (2) after46
weeks of treatment with β1-selective β-blockers and (3) after 46
weeks of treatment with nadolol. We recorded resting and maximum
heart rates and the most severe ventricular arrhythmia occurring.
Severity of arrhythmias was scored as 1 point for no arrhythmias or
only single ventricular extrasystoles, 2 points for 410 ventricular
extrasystoles per minute or bigeminy, 3 points for couplets, and 4
points for nonsustained ventricular tachycardia or sustained ventric-
ular tachycardia.
RESULTS Resting heart rate was similar during treatment with
nadolol and β1-selective β-blockers (54 10 beats/min vs 56 14
beats/min; P ¼ .50), while maximum heart rate was lower during
treatment with nadolol compared with β1-selective β-blockers (122
 21 beats/min vs 139  24 beats/min; P ¼ .001). ArrhythmiasThis work was supported by the Norwegian Health Association, Nor-
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Council of Norway; and Simon Fougner Hartmanns Family Foundation.
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1547-5271 B 2016 Heart Rhythm Society. Open access under CC BY-NC-ND license.during exercise stress testing were less severe during treatment
with nadolol compared with during treatment with β1-selective
β-blockers (arrhythmic score 1.6 0.9 vs 2.5 0.8; Po .001) and
before the initiation of β-blocker treatment (arrhythmic score
1.6  0.9 vs 2.7  0.9; P ¼ .001); however, no differences were
observed during treatment with β1-selective β-blockers compared
with before the initiation of β-blocker treatment (arrhythmic score
2.5  0.8 vs 2.7  0.9; P ¼ .46).
CONCLUSION The incidence and severity of ventricular arrhythmias
decreased during treatment with nadolol compared with during treat-
ment with β1-selective β-blockers. β1-Selective β-blockers did not
change the occurrence or severity of arrhythmias compared with no
medication.
KEYWORDS Catecholaminergic polymorphic ventricular tachycardia;
Ventricular arrhythmias; β-Blocker treatment; Exercise stress test
ABBREVIATIONS CPVT ¼ catecholaminergic polymorphic ventricular
tachycardia; ECG ¼ electrocardiogram/electrocardiographic;
ICD ¼ implantable cardioverter-deﬁbrillator; NSVT ¼ nonsustained
ventricular tachycardia; RyR2¼ ryanodine receptor 2; SCA¼ sudden
cardiac arrest; VES ¼ ventricular extrasystole; VT ¼ ventricular
tachycardia
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Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is an inheritable arrhythmogenic cardiac disease
with an estimated prevalence of 1:10,000.1 Despite the low
prevalence, CPVT is an important cause of sudden cardiac
arrest (SCA) in young individuals, and cardiac event rates as
high as 80% before the age of 40 years have been reported if
left untreated.2 However, in the patient populations seen in
the era of genetic screening, event rates may be considerablyhttp://dx.doi.org/10.1016/j.hrthm.2015.09.029
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due to ventricular arrhythmias during physical activity or
emotional stress, but SCA may also be the ﬁrst manifestation
of the disease.2,4 Exercise stress testing is considered the
most sensitive clinical tool to detect CPVT and reveals
frequent premature ventricular contractions,2,5–7 arrhythmias
of increasing severity as workload increases, and ultimately
bidirectional or polymorphic ventricular tachycardia (VT),
which might degenerate to ventricular ﬁbrillation.1,5,8
In about 60% of cases,9 CPVT is caused by probable
pathogenic variants in the ryanodine receptor 2 (RyR2) gene.
Catecholaminergic stimulation of the β-receptor aggravates
pathological diastolic calcium release from an unstable
RyR2 channel, causing malignant ventricular arrhythmias.4
The proarrhythmic mechanism described may not be entirely
similar in patients with CPVT with probable pathogenic
variants in other genes or variant-negative patients. In the
new guidelines, β-blocker treatment is a class Ic recommen-
dation in patients with clinically diagnosed CPVT and
should also be considered in genotype-positive, phenotype-
negative family members (class IIa, level of evidence C).10
β-Blockers are suggested to provide arrhythmia protection
by reducing the inﬂuence of catecholamines11 by blocking
the β-receptor–induced intracellular signaling, which leads to
destabilization of RyR2. However, β-blockers differ in many
aspects, including selectivity, half-life, lipid solubility, and
bioavailability, and limited data exist on how antiarrhythmic
effects differ in speciﬁc β-blockers.12–14 A previous report3
indicated that the unselective β-blocker nadolol might
prevent cardiac events more effectively than other
β-blockers in patients with CPVT. Superior effects of
unselective β-blockers such as nadolol have also been
reported in the long QT syndrome.12,15
In this study, we aimed to investigate the effects of
different β-blockers on arrhythmias in patients with CPVT.
We serially investigated the frequency and severity of
ventricular arrhythmias before the initiation of β-blocker
treatment, during treatment with β1-selective β-blockers, and
during treatment with nadolol. We hypothesized that nadolol
is more effective than β1-selective β-blockers in suppressing
ventricular arrhythmias in patients with CPVT.Methods
Patient population and recruitment
Patients with CPVT were included for repeated exercise
stress tests during a visit to the Department of Cardiology,
Oslo University Hospital, Rikshospitalet, Norway, between
2008 and 2012. Outcome data were collected from patients’
history and were recorded during follow-up. The CPVT
diagnosis was reviewed in 2014 according to new expert
consensus recommendations16 to ensure an up-to-date CPVT
diagnosis in all participants. These recommendations include
patients harboring a probable pathogenic variant and patients
with a structurally normal heart and a normal resting
electrocardiogram (ECG) with unexplained exercise-
induced bidirectional VT or polymorphic ventricularpremature beats.16 All patients fulﬁlled these criteria. Data
on effects of different β-blockers were collected
retrospectively.
Index patients, deﬁned as the ﬁrst patient in a family to be
diagnosed, were genetically tested and variant-positive
family members were included after family cascade screen-
ing. We performed serial investigations of the same patients
before initiation of β-blocker treatment and on 2 different
β-blocking medications. All changes in medications were
performed on clinical indication on the basis of the article by
Hayashi et al in 2009,3 indicating that CPVT patients treated
with nadolol had fewer cardiac events than those treated with
other β-blockers. Patients included after 2009 were consid-
ered for the direct initiation of nadolol. However, owing to
legislation formalities regarding availability of nadolol, new
patients were treated with β1-selective β-blockers as a bridge to
nadolol. All patients were intended to switch from our standard
treatment with metoprolol SR to nadolol. Exceptions were
patients with contraindications to unselective β-blockers or
patients who did not agree to medication change. Compliance
with β-blocker treatment was monitored by direct feedback from
each patient at the clinical visits.
CPVT-related symptoms were deﬁned as cardiac syn-
cope, documented ventricular arrhythmia (including non-
sustained ventricular tachycardia [NSVT]) from implantable
cardioverter-deﬁbrillator (ICD) recordings or Holter mon-
itoring, appropriate ICD shocks, aborted cardiac arrest, or
sudden cardiac death. For calculation of annual event rates,
only syncope, appropriate ICD shocks, aborted cardiac
arrests, and sudden cardiac deaths were included. NSVT
was deﬁned as previously reported.17 Signiﬁcant arrhyth-
mias during exercise stress testing were deﬁned as 410
single ventricular extrasystoles (VESs) per minute, bige-
miny, couplets, NSVT, and VT. The use of medication was
recorded. The β-blocker dosage was up-titrated until the
maximum tolerated dosage in each individual, considering
side effects such as bradycardia and fatigue. In patients with
ICDs, the numbers of appropriate and inappropriate shocks
were recorded. Arrhythmic window, reﬂecting the range of
heart rate during which arrhythmias occurred, was assessed
by exercise stress tests.Electrocardiography and exercise stress test
A 12-lead resting ECG was obtained at time of the exercise
stress test. We intended to perform 3 bicycle exercise stress
tests in each patient: (1) before the initiation of β-blocker
treatment, (2) after 46 weeks of treatment with maximum
tolerated dosages of β1-selective β-blockers, and (3) after46
weeks of treatment with maximum tolerated dosages of
nadolol. Bicycle exercise stress tests were performed starting
at a workload of 50 W, and increased by 25 W every second
minute until exhaustion, e.g. shortness of breath or fatigue, or
until sustained VT. When multiple exercise stress tests were
performed using the same medication, we chose the test for
analysis in the following order: the exercise stress test at the
highest β-blocker dosage, highest workload, and longest
Table 1 Baseline clinical characteristics of 34 patients with CPVT
Characteristic Value
Index patients 10 (29)
Variant-positive family members 24 (71)
Age at diagnosis (y) 34  19
Sex: female 15 (44)
Variant positive 30 (88)
Symptomatic when untreated 18 (53)
Aborted cardiac arrest 4 (12)
Syncope 13 (38)
Documented ventricular arrhythmias with
hemodynamic deterioration
1 (3)
ICD 9 (26)
Values are presented as mean  SD or as n (%).
CPVT ¼ catecholaminergic polymorphic ventricular tachycardia; ICD ¼
implantable cardioverter-deﬁbrillator.
435Leren et al Antiarrhythmic Effects of β-Blockers in CPVTfollow-up time. All ECG tracings were analyzed by at least 2
independent investigators.
A 12-lead ECG was obtained at the beginning, monitored
continuously, and recorded throughout the examination.
Resting and maximum heart rates and maximum workloads
were recorded, as well as the heart rate at the appearance of
arrhythmias. In addition, the most severe arrhythmia during the
exercise stress test was recorded. We deﬁned the arrhythmic
window as the range of heart rate between the heart rate at the
ﬁrst VES and the maximum achieved heart rate.
Severity of ventricular arrhythmias during the exercise
stress tests was scored as 1 point for no arrhythmias or only
single VESs, 2 points for410 VESs per minute or bigeminy,
3 points for couplets, and 4 points for NSVT or VT, reﬂecting
severity of arrhythmias.18
Holter monitoring
Repeated 24-hour Holter monitoring was performed before
the initiation of β-blocker treatment and during treatment
with maximum tolerated dosages of β1-selective β-blockers
and nadolol. Holter recordings were analyzed for the number
of ventricular beats and severity of arrhythmias (scored
similarly to the exercise stress test).
Genetic analyses
Genetic testing was performed as part of the diagnostic workup
for suspected CPVT. DNA sequencing of 29 of the 105 exons of
the RyR2 gene was performed in all index patients by using the
BigDye Terminator v3.1 Cycle Sequencing Kit and a Genetic-
Analyzer 3730 from Applied Biosystems (Foster City, CA). The
calsequestrin 2 gene was not analyzed. Cascade genetic screen-
ing was performed in family members of variant-positive index
patients according to clinical standards and Norwegian legisla-
tion. Family members of variant-negative patients were not
included. Decisions on pathogenicity were based on the total
evaluation including previous reports, genomic databases,19,20 in
silico programs (PolyPhen and SIFT), and family cosegregation
studies.
Statistical analyses
Continuous data were presented as mean SD or as median
(quartile 1, quartile 3). Comparisons between groups were
performed using linear mixed models for dependent con-
tinuous variables or the McNemar test for dependent nominal
variables. Linear mixed models allowed for the inclusion of
patients with o3 exercise stress test results available for
analyses. Two-sided P valuesr.05 were considered statisti-
cally signiﬁcant.
All participants gave written informed consent. The study
complied with the Declaration of Helsinki and was approved
by the regional committees for medical research ethics.
Results
Clinical characteristics
A total of 34 patients with CPVT (mean age 34  19 years;
15 (44%) women) were included in the study (Table 1), and30 (88%) had a probable pathogenic variant in the RyR2 gene.
Five different variants were identiﬁed in 5 families. Ten (29%)
were index patients, and 24 (71%) were variant-positive family
members. The median follow-up was 8 years (range 2–15
years), including a median of 49 months in patients treated
with β1-selective β-blockers (quartile 1, quartile 3: 30, 81
months) and a median of 35 months in patients treated with
nadolol (quartile 1, quartile 3: 19, 46 months).
Before the initiation of β-blocker treatment, 13 (38%)
patients had experienced syncope, 4 (12%) had aborted cardiac
arrest, and 1 (3%) had a documented ventricular arrhythmia.
When treated with β1-selective β-blockers, 3 (11%) patients
had syncope, including 1 (4%) who also had an appropriate
ICD shock (non adherent to treatment). One (4%) patient
survived a cardiac arrest and had several episodes of NSVT,
and 3 (11%) patients had documented ventricular arrhythmias
(NSVT). One patient died of stroke during follow-up
(Figure 1). When treated with nadolol, only 1 (6%) patient
had syncope. In case of nonadherence to β-blocker treatment
(n¼ 2), an individual approach with intensiﬁed follow-up was
applied and ICD implantation and left cardiac sympathetic
denervation were considered. Annual event rates were 0.04
during treatment with β1-selective β-blockers and 0.02 during
treatment with nadolol (P ¼ .64).
An ICD was implanted in 9 (26%) patients, of whom 4
received no shock therapy from their ICD during follow-up.
When treated with β1-selective β-blockers, 1 patient had
appropriate shock, 1 patient had both appropriate and
inappropriate shocks, and 2 patients had only inappropriate
shocks. When treated with nadolol, 1 patient had both
appropriate and inappropriate shocks (non adherent to treat-
ment) and 1 had an inappropriate shock.Exercise stress tests
Exercise stress test 1 was performed in β-blocker–naive
patients. Exercise stress tests 2 and 3 were performed with
the β-blocker taken in the morning the same day. In 57 of 68
exercise stress tests (84%), ventricular arrhythmias increased
in severity during exercise stress tests. During exercise stress
test 2, the majority of patients was treated with metoprolol
Figure 1 Flowchart of inclusion and follow-up of 34 patients with CPVT during all 3 exercise stress tests. CPVT ¼ catecholaminergic polymorphic
ventricular tachycardia.
Heart Rhythm, Vol 13, No 2, February 2016436SR (dosage 1.4  0.7 mg/kg) while 2 (7%) patients were
treated with the β1-selective β-blocker bisoprolol (dosage
0.14  0.01 mg/kg) because of side effects of metoprolol.
Eleven patients (32%) remained on β1-selective β-blockers
(Figure 1) because of either pulmonary disease, other
contraindications to unselective β-blocker treatment, or
unwillingness of the patients to change their previous
medication on which they had good arrhythmia control
(Figure 1). The 11 (32%) patients remaining on β1-selective
β-blockers did not differ in age at diagnosis, nor in total
follow-up time, from those who changed medication.
Three patients (15%) were treated with ﬂecainide in
addition to nadolol and were consequently excluded from
analyses of the effects of nadolol.Table 2 Results of exercise stress tests and Holter monitoring perform
during treatment with β1-selective β-blockers, and during nadolol treatm
Characteristic
Exercise stress test 1:
No medication
(n ¼ 25)
Dosage of β-blocker (mg/kg)
Resting heart rate (beats/min) 63  12
Heart rate at the ﬁrst VES (beats/min) 128  20
Maximum heart rate (beats/min) 164  17
Arrhythmic window (beats/min) 37  22
Arrhythmic score: Exercise stress test 2.7  0.9
Arrhythmic score: Holter 1.5  0.7
Maximum work load (W) 146  42
Values are presented as mean  SD.
P values obtained using linear mixed models.
CPVT ¼ catecholaminergic polymorphic ventricular tachycardia; NA ¼ not app
*P r .05 vs no medication.
†P r .05 vs β1-selective β-blockers.Occurrence and severity of arrhythmias
Resting heart rate was lower during treatment with
β-blockers than before the initiation of β-blocker treatment,
regardless of β-blocker type (Pr .01 for both) (Table 2), but
it was similar during treatment with β1-selective β-blockers
and nadolol (56  14 beats/min vs 54  10 beats/min;
P ¼ .50). Also, maximum heart rate was lower during
treatment with β-blocker than before the initiation of
β-blocker treatment (P o .001 for both) and lowest during
treatment with nadolol (P ¼ .001 vs β1-selective β-blocker
treatment). Blood pressure was similar during β1-selective
β-blocker and nadolol treatment (systolic 115  19 mm Hg
vs 121 24 mm Hg; P ¼ .21 and diastolic 70  16 mm Hg
vs 72  12 mm Hg; P ¼ .31, respectively). Maximum worked before the initiation of β-blocker treatment (no medication),
ent in 34 patients with CPVT
Exercise stress test 2:
β1-Selective β-blockers
(n ¼ 28)
Exercise stress test 3:
Nadolol
(n ¼ 17) P
Metoprolol SR: 1.4  0.7 1.3  0.5 NA
Bisoprolol: 0.14  0.01
56  14* 54  10* .01
113  19* 113  21 .003
139  24* 122  21*† o.001
32  26 17  10*† .001
2.5  0.8 1.6  0.9*† o.001
1.4  0.8 1.2  0.6* .12
163  49 148  38 .26
licable; VES ¼ ventricular extrasystole.
437Leren et al Antiarrhythmic Effects of β-Blockers in CPVTload was similar during all 3 exercise stress tests (P4 .10 for
all comparisons) (Table 2).
Before the initiation of β-blocker treatment, 23 (92%)
patients with CPVT had ventricular arrhythmias during
exercise stress testing (ranging from 410 single VESs per
minute to NSVT), including 6 (25%) with NSVT. The
average arrhythmic score before the initiation of β-blocker
treatment was 2.7  0.9. Three (12%) patients had no
signiﬁcant arrhythmias (arrhythmic score 1: no arrhythmias,
or r10 single VESs per minute). During treatment with
β1-selective β-blockers (Table 2), 27 (96%) patients had
ventricular arrhythmias, including 4 (14%) with NSVT. The
arrhythmic score was similar to before the initiation of
β-blocker treatment (P ¼ .46) (Table 2 and Figure 2). Two
(7%) patients had no signiﬁcant arrhythmias. During nadolol
treatment, 10 (59%) patients had no signiﬁcant arrhythmias
(P ¼ .02 vs before the initiation of β-blocker treatment and
P ¼ .008 vs β1-selective β-blocker treatment) and only 1
(6%) patient had NSVT (P ¼ .38 vs before the initiation of
β-blocker treatment). During nadolol treatment, the arrhyth-
mic score was 1.6  0.9, which was lower compared with
both β1-selective β-blocker treatment (2.5  0.8; Po .001)
and before the initiation of β-blocker treatment (2.7  0.9;
P ¼ .001) (Table 2 and Figure 2). This result was unchanged
when only patients who serially underwent all 3 exercise
stress tests were included (Online Supplemental Table 1).
Arrhythmic window, reﬂecting range of heart rate from the
occurrence of arrhythmias to the maximum heart rate, was
smaller during nadolol treatment (17  10 beats/min) than
before the initiation of β-blocker treatment (37  22 beats/
min; P o .001) (Table 2 and Figure 3) and than during
β1-selective β-blocker treatment (32 26 beats/min; P¼ .03)
(Table 2 and Figure 3). The threshold for arrhythmias was
lower during treatment with β1-selective β-blockers than
before the initiation of β-blocker treatment (113  19 beats/
min vs 128  20 beats/min; Po .001), while no differencesFigure 2 Incidence and severity of arrhythmias during exercise stress tests in 34
treatment with β1-selective β-blockers (middle), and during treatment with nado
treatment than both before the initiation of β-blocker treatment and during β1-selecti
β-blocker treatment and before the initiation of β-blocker treatment. CPVT ¼ cate
ventricular tachycardia; VES ¼ ventricular extrasystoles.were observed during treatment with β1-selective β-blockers
and nadolol (113  19 beats/min vs 113  21 beats/min;
P ¼ 1.0) (Table 2).β-Blocker dosages, heart rates, and arrhythmias
During exercise stress test 3, the dosage of nadolol was 1.3
0.5 mg/kg compared with the metoprolol SR dosage of 1.4
0.7 mg/kg during exercise stress test 2. Dosages of 0.8 mg/kg
of nadolol and 1 mg/kg of metoprolol SR are considered
equipotent,21,22 and therefore, calculated as equivalents, the
dosages of nadolol and metoprolol SR were similar
(P = .15). In intraindividual analyses, 7 (50%) patients had
equivalent dosages of nadolol and metoprolol SR. Of these,
6 (86%) had lower maximal heart rate and 5 (71%) had a less
severe arrhythmia during treatment with nadolol. This was
similar to the 6 (43%) patients who had higher dosages of
nadolol; 5 (83%) had lower maximal heart rate and 5 (83%)
had less severe arrhythmias during treatment with nadolol.
One (7%) patient had higher dosages of metoprolol SR but
still had lower maximum heart rate and less severe arrhyth-
mias during treatment with nadolol.
In 3 patients, maximum heart rate was similar (o5 beats/
min difference) during treatment with β1-selective β-blockers
and nadolol. In 2 of these patients, severity of arrhythmias
decreased (bigeminy to single VESs and couplets to bige-
miny) and in 1 patient severity was unchanged.Holter monitoring
The arrhythmic score calculated from Holter recordings was
similar in patients before the initiation of β-blocker treatment
and during treatment with β1-selective β-blockers (P = .42),
but the arrhythmic score was lower during treatment with
nadolol than before the initiation of β-blocker treatment (P =
.05) (Table 2). The incidence of VESs during 24-hour Holter
monitoring did not differ before initiation of β-blockerpatients with CPVT before the initiation of β-blocker treatment (left), during
lol (right). Arrhythmias were less frequent and less severe during nadolol
ve β-blocker treatment, whereas there was no difference between β1-selective
cholaminergic polymorphic ventricular tachycardia; NSVT ¼ nonsustained
Figure 3 Arrhythmic window in patients with CPVT before the initiation of β-blocker treatment, during treatment with β1-selective β-blockers, and during
treatment with nadolol. Green bars indicate arrhythmia-free heart rates during exercise stress tests, and red bars indicate heart rates during which arrhythmias
occurred. Green vertical arrows indicate resting heart rate, red vertical arrows indicate heart rate at the start of arrhythmias, and black vertical arrows indicate
maximum heart rate. Red horizontal lines indicate arrhythmic window. The arrhythmic window was smaller during treatment with nadolol than both before the
initiation of β-blocker treatment and during β1-selective β-blocker treatment. *Po .05 for both. AW ¼ arrhythmic window; bpm ¼ beats per minute; CPVT ¼
catecholaminergic polymorphic ventricular tachycardia.
Heart Rhythm, Vol 13, No 2, February 2016438treatment (median 4 VESs; quartile 1, quartile 3: 0, 17 VESs),
during treatment with β1-selective β-blockers (median 2
VESs; quartile 1, quartile 3: 0, 34 VESs), and during nadolol
treatment (median 0 VESs; quartile 1, quartile 3: 0, 12 VESs).
Discussion
We present for the ﬁrst time a study with serial investigations of
patients with CPVT before initiation of β-blocker treatment,
treated with β1-selective β-blockers, and treated with the
unselective β-blocker nadolol. Repeated exercise stress tests
and Holter monitoring showed a reduced frequency and severity
of arrhythmias in CPVT during nadolol treatment compared
with both β1-selective β-blocker treatment and no treatment.
Occurrence and severity of arrhythmias
Before the initiation of β-blocker treatment, almost every
patient with CPVT had exercise-induced arrhythmias, high-
lighting the high sensitivity of the exercise stress test to
diagnose patients with CPVT.23 Severity of arrhythmias
increased as workload and heart rate increased in the
majority of exercise stress tests performed, similar to
previous studies.1,8 In a minority of exercise stress tests,
arrhythmias decreased in severity or disappeared at maximal
exercise, as also shown previously.24 The occurrence of
arrhythmias was similar during treatment with β1-selective
β-blockers and before the initiation of β-blocker treatment, as
also reported by others.25–27 However, the occurrence of
arrhythmias was lower during treatment with nadolol than
both before the initiation of β-blocker treatment and during
treatment with β1-selective β-blockers, and severity of
arrhythmias, reﬂected as arrhythmic score, was also lower.
Arrhythmias during exercise stress tests are only surro-
gate markers of arrhythmias in daily life. However, Hayashi
et al3 demonstrated that results of exercise stress testing were
associated with future cardiac events and that patients treatedwith nadolol had a lower daily life event rate than patients
treated with other β-blockers. In our study, arrhythmic events
in daily life were present in 7 (25%) patients during treatment
with β1-selective β-blockers, but in only 1 (6%) patient
during treatment with nadolol. However, follow-up of
patients treated with nadolol was shorter, thus limiting the
interpretation of this ﬁnding.Effects of different β-blockers in patients with CPVT
Nadolol has been referred to as the β-blocker of choice in patients
with CPVT.28,29 This recommendation was based on a single
observational study,3 reporting lower cardiac event rate in 63
patients with CPVT treated with nadolol than in 18 patients with
CPVT treated with other β-blockers. Our study strengthens this
observation by serially investigating patients with CPVT and
supports nadolol as the β-blocker of choice in CPVT.
Possible explanations for the observed effects of nado-
lol include the following: (1) nadolol has a stronger effect
on chronotropic response as compared with metoprolol and
bisoprolol; (2) nadolol was better tolerated, and metoprolol
and bisoprolol were not sufﬁciently up-titrated; or (3) a
combination of these and other unknown factors. In our
patients, nadolol resulted in lower maximum heart rate than
β1-selective β-blockers, which might indicate a more
pronounced chronotropic effect. Other parameters such
as blood pressure, resting heart rate, and maximum work-
load were similar during treatment with nadolol and
β1-selective β-blockers, indicating comparable β-blocking
action. Heart rate at the occurrence of ﬁrst arrhythmias was
similar during treatment with β1-selective β-blockers and
nadolol; hence, the arrhythmic window, reﬂecting the
range of heart rate during which arrhythmias occurred,
was smaller during nadolol treatment. This signiﬁcant
effect of nadolol on chronotropy may reduce the oppor-
tunity for more severe arrhythmias to occur during nadolol
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this study. Other possible factors of different β-blocker
actions include that metoprolol SR and bisoprolol as β1-
selective β-blockers and nadolol as an unselective β-
blocker differ in several pharmacological aspects. It has
been speculated that the additional, small sodium-blocking
effect of nadolol has a membrane-stabilizing effect,
important for arrhythmia protection.12,13 Furthermore,
nadolol has a long half-life (20–24 hours),30 which reduces
the risk of breakthrough symptoms during potential β-
blocker nonadherence. β-Blocker nonadherence is a con-
cerning risk in patients with CPVT.3,6,31
We carefully up-titrated the dosages of β-blockers in each
individual patient over several visits to reach the maximum
tolerated dosages of both metoprolol SR and nadolol and the
ﬁnal dosages were considered equipotent. In an intraindi-
vidual comparison, both maximum heart rate and severity of
arrhythmias were lower during treatment with nadolol than
during treatment with metoprolol SR in patients with
equivalent dosages of the 2 β-blockers, and this was also
observed in a patient treated with a higher dosage of
metoprolol SR than of nadolol. Also, in patients with similar
maximum heart rate, arrhythmias were less severe during
nadolol treatment than during β1-selective β-blocker treat-
ment. Therefore, we do not believe that the reduced
occurrence and severity of arrhythmias during nadolol treat-
ment were attributed only to higher dosages of medication.
On the other hand the reduction in maximum heart rate
during nadolol treatment could also be interpreted as nadolol
being better tolerated and more easily up-titrated. Taken
together, our results indicate that nadolol may be most
beneﬁcial in patients with CPVT, although the mechanisms
are not clear. Our study included a limited number of patients
and larger studies are needed to further explore these effects.
Clinical implications
Ventricular arrhythmias in patients with CPVT are highly
malignant and may cause SCA. Treatment to prevent
occurrence of arrhythmias, including high dosages of
β-blockers and ﬂecainide18 as well as eventual left cardiac
sympathetic denervation,32 is of vital importance, in partic-
ular since ICD therapy in CPVT is not straightforward.33 Our
study showed by serial investigations of CPVT patients that
the occurrence and severity of arrhythmias decreased during
nadolol treatment compared with during treament with
equipotent dosages of β1-selective β-blockers. β-Blocker
side effects did not seem to increase during treatment with
nadolol, and equipotent dosages of nadolol were well
tolerated compared with β1-selective β-blockers. However,
our population included mainly patients with CPVT1 (RyR2
probable pathogenic variant positive), and future studies
should include more gene-elusive patients with CPVT.
Study limitations
This study included a limited number of patients, thereby
reducing the strength of the conclusions. However, CPVT isa rare condition and the serial investigation design of our
study strengthens our results. A few patients were included
in the study after the initiation of β1-selective β-blockers, and
not all patients were switched to nadolol, making the data set
incomplete. However, the results did not differ when only
patients with all 3 exercise stress tests completed were
included (Online Supplemental Table 1). It is a potential
bias that the patients with most severe arrhythmias
(and insufﬁcient arrhythmic control during treatment with
β1-selective β-blockers) were switched to nadolol, while
some of those with less severe arrhythmias remained on
β1-selective β-blockers. However, nadolol treatment still
resulted in fewer and less severe arrhythmias despite the
potential bias toward more severe arrhythmias in those who
switched to nadolol.
We analyzed only 1 exercise stress test per patient per
medication. The results may vary between 2 exercise stress
tests,25 although arrhythmic threshold in CPVT is surprisingly
reproducible in our experience. The exercise stress tests were
performed unblinded to the current medication. The ECG
tracings were subsequently analyzed by 2 independent inves-
tigators to ensure the accuracy of arrhythmia interpretation.
We did not sequence the entire exome of RyR2; hence,
variant-negative patients may potentially have a probable
pathogenic variant in a nonsequenced area.
Conclusion
In this study, nadolol treatment was associated with a lower
incidence and severity of ventricular arrhythmias compared
with β1-selective β-blocker treatment in patients with CPVT.
β1-Selective β-blocker treatment did not seem to change the
occurrence or severity of arrhythmias compared with no
treatment. Our results indicate that nadolol may be superior
to β1-selective β-blockers in preventing arrhythmias in
patients with CPVT.
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11:58–66.CLINICAL PERSPECTIVES
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inheritable arrhythmogenic disease predisposing to
malignant ventricular arrhythmias during exercise or emotional stress, presenting as syncope or sudden cardiac death.
β-Blocker treatment is the mainstay of medical therapy, but differences in antiarrhythmic efﬁcacy between different
β-blockers may exist. We performed for the ﬁrst time a study with serial exercise stress tests and Holter examinations in
patients with CPVT assessing the occurrence and severity of ventricular arrhythmias before the initiation of β-blocker
treatment, during treatment with β1-selective β-blockers, and during treatment with the unselective β-blocker nadolol. Our
study showed that occurrence and severity of arrhythmias decreased during equipotent dosages of nadolol compared with
β-1 selective β-blockers. Maximum heart rate during exercise stress testing decreased on nadolol, while heart rate at the
occurrence of arrhythmias remained similar to that observed during treatment with β1-selective β-blockers. The reduction in
maximum heart rate on nadolol could be a result of better tolerance and easier up-titration of nadolol. The study strengthens
the observations that nadolol seems to provide better antiarrhythmic effects than unselective β-blockers and that nadolol
may be the ﬁrst-choice β-blocker in patients with CPVT. Furthermore, favorable effects of nadolol in patients with CPVT
emphasize the importance of continued availability of this β-blocker, which has occasionally been limited. Optimal medical
therapy is of vital importance in CPVT, in particular since ICD therapy is ambiguous with an inherent risk of inappropriate
shocks and potentially devastating electrical storms.
